12:00 AM
 | 
Feb 02, 2004
 |  BioCentury  |  Product Development

Plucked from the discard pile

Bristol-Myers Squibb Co. may have jumped the gun when it dropped development of tesmilifene after the compound failed to improve response rates and progression-free survival in a Phase III breast cancer trial. As it turns out, tesmilifene actually increased overall survival.

Now YM Biosciences Inc. is preparing another go with tesmilifene in breast cancer, after initially picking up the discarded compound based on its promising activity in prostate cancer.

In 2000, YM (TSE:YM; LSE:YMBA, Mississauga, Ontario), then York Medical Inc., licensed tesmilifene from CancerCare Manitoba and the University of Manitoba based on interim results from a Phase II trial in prostate cancer also started by the pharma company (see BioCentury, Nov. 20, 2000). BMY (Princeton, N.J.) already had returned its rights to the institutions, apparently based on initial results from the breast cancer trial.

Indeed, the early returns were underwhelming, as enrollment in the breast...

Read the full 714 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >